Teva Pharma (TEVA) PT Lowered to $9 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Teva Pharma (TEVA) Weakness 'Overdone' - Oppenheimer
June 12, 2019 12:08 PM EDTOppenheimer analyst Esther Rajavelu reiterated an Outperform rating and $12.00 price target on Teva Pharma (NYSE: TEVA), saying the weakness is "overdone."
Rajavelu commented, "Following up on our recent upgrade of TEVA to Outperform (6/3 at $8.65), we note today's weakness may present an attractive entry point... More
